Axsome Therapeutics (FRA:19X) Net Interest Margin (Bank Only) %


FRA:19X Axsome Therapeutics Inc FRA:19X
54 GF Score
Price €214.00
GF Value €185.89
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:19X
54GF Score
Axsome Therapeutics Inc FRA:19X
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Axsome Therapeutics (FRA:19X) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of €214.00 is trading 15.1% above its estimated GF Value™ of €185.89. GuruFocus considers Axsome Therapeutics to be Modestly Overvalued.

Key valuation signals for FRA:19X:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €185.89 vs. price of €214.00 (15.1% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the FRA:19X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
54GF Score

Get the complete analysis for FRA:19X

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€214.00
Price
€185.89
GF Value